Peter A. Fasching
Advertisement
Articles by Peter A. Fasching
46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study
ByHeather McArthur, MD, MPH,Peter A. Fasching,Rebecca Dent, MD,Javier Cortés, MD,Lajos Pusztai, MD, DPhil,Sherko Kuemmel,Carsten Denkert,Yeon Hee Park,Rina Hui,Nadia Harbeck, MD, PhD,Masato Takahashi,Seock-Ah Im,Michael Untch, MD, PhD,Marie-Ange Mouret-Reynier,Theodoros Foukakis,Marta Ferreira,Fatima Cardoso,Yu Ding,Cecilia Pinheiro,Jaime Mejia,Joyce A. O’Shaughnessy,Peter Schmid, MD
11 Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756
ByFatima Cardoso,Joyce O’Shaughnessy, MD,Heather McArthur, MD, MPH,Peter Schmid, MD,Javier Cortés, MD,Nadia Harbeck, MD, PhD,Melinda L. Telli, MD,David W. Cescon,Peter A. Fasching,Zhimin Shao,Delphine Loirat,Yeon Hee Park,Manuel Gonzalez Fernandez,Gábor Rubovszky,Seock-Ah Im,Rina Hui,Toshimi Takano,Fabrice André,Hiroyuki Yasojima,Zhenzhen Liu,Yu Ding,Liyi Jia,Vassiliki Karantza,Konstantinos Tryfonidis,Aditya Bardia, MD, MPH
21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial
ByGabriel N. Hortobagyi, MD, FACP,Daniil Stroyakovskiy,Denise A. Yardley, MD,Chiun-Sheng Huang,Peter A. Fasching,John Crown,Aditya Bardia, MD, MPH,Stephen Chia,Seock-Ah Im,Miguel Martin, MD, PhD,Sherene Loi, MD, PhD,Binghe Xu,Sara A. Hurvitz, MD,Carlos Barrios,Michael Untch, MD, PhD,Rebecca Moroose,Frances Visco,Federico Parnizari,Farhat Ghaznawi,Zheng Li,Sorcha Waters,Arunava Chakravartty,Dennis J. Slamon, MD, PhD
Advertisement
Latest Updated Articles
23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE TrialPublished: June 23rd 2025 | Updated:
Advertisement
Advertisement
